AN ANALYSIS AND SIGNIFICANCE OF IMMUNOHISTOCHEMISTRY ER, PR AND HER2 TESTING FOR BREAST MALIGNANCY IN A TERTIARY CARE CENTER
- Associate Professor, Department Of Pathology, Madurai Medical College.
- Professor, Department Of Pathology, Madurai Medical College.
Abstract
Background: A significant development in the Breast malignancy, the expression of Hormone receptors in the tumor cells for the management and prognosis.
Aim of Study : This study was conducted to correlate Immunohistochemical expression of markers such as estrogen receptor( ER) , progesterone receptor (PR ),and Her-2/neu with clinical mainly age, sex and Histopathological parameters .
Materials and Methods: This prospective study was done at the tertiary care hospital from January 2019 to January 2020. 296 cases of Breast malignancy were studied. Immunohistochemistry (IHC) for ER, PR, and Her-2/neu was performed. The laboratory reporting was done according to the standard scoring system from CAP protocol 2019.
Results: According to the molecular basis of Breast tumor, the ER positive and Her-2 Negative was observed in 24.6% ( 73/296) cases , ER Positive and Her-2/neu Positive in 22.9 % ( 68/296) cases, whereas ER negative and Her-2 /neu positive in 21.6 % ( 64/296) cases. Triple marker (ER , PR and Her-2) negative cases were seen in 23.9 % ( 71/296). Triple marker positive cases were 6.75 % ( 20/296).
Conclusion: IHC markers studies in Breast malignancy is still gold standard for treating the patients and prognostic aspect.
Keywords
Article Analytics
How to Cite This Article
G. Jeyanthi, S. Malliga and K. Rani (2020); AN ANALYSIS AND SIGNIFICANCE OF IMMUNOHISTOCHEMISTRY ER, PR AND HER2 TESTING FOR BREAST MALIGNANCY IN A TERTIARY CARE CENTER, Int. J. of Adv. Res., 8 (09), 1447-1452, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/11810
Corresponding Author
This work is licensed under a Creative Commons Attribution 4.0 International License.